I-Mab (IMAB) - Total Assets
Based on the latest financial reports, I-Mab (IMAB) holds total assets worth $277.41 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
I-Mab - Total Assets Trend (2017–2024)
This chart illustrates how I-Mab's total assets have evolved over time, based on quarterly financial data. Also see I-Mab stock valuation for the company's overall valuation and market capitalisation.
I-Mab - Asset Composition Analysis
Current Asset Composition (December 2024)
I-Mab's total assets of $277.41 Million consist of 83.1% current assets and 16.9% non-current assets. Review IMAB total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.1% |
| Accounts Receivable | $1.17 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how I-Mab's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See I-Mab share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: I-Mab's current assets represent 83.1% of total assets in 2024, an increase from 67.5% in 2017.
- Cash Position: Cash and equivalents constituted 32.1% of total assets in 2024, up from 30.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
I-Mab Competitors by Total Assets
Key competitors of I-Mab based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
I-Mab - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.47 | 15.99 | 9.28 |
| Quick Ratio | 14.47 | 15.99 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $216.68 Million | $176.44 Million | $4.77 Billion |
I-Mab - Advanced Valuation Insights
This section examines the relationship between I-Mab's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.76 |
| Latest Market Cap to Assets Ratio | 2.15 |
| Asset Growth Rate (YoY) | -91.9% |
| Total Assets | $212.68 Million |
| Market Capitalization | $456.45 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values I-Mab's assets at a significant premium (2.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: I-Mab's assets decreased by 91.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for I-Mab (2017–2024)
The table below shows the annual total assets of I-Mab from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $212.68 Million | -91.86% |
| 2023-12-31 | $2.61 Billion | -35.86% |
| 2022-12-31 | $4.07 Billion | -27.64% |
| 2021-12-31 | $5.63 Billion | -11.12% |
| 2020-12-31 | $6.33 Billion | +264.52% |
| 2019-12-31 | $1.74 Billion | -26.87% |
| 2018-12-31 | $2.38 Billion | +131.72% |
| 2017-12-31 | $1.03 Billion | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more